Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, Ishikawa T, Toyoda H, Hatanaka T, Kakizaki S, Naganuma A, Tada F, Tanaka H, Nakamura S, Nouso K, Tanaka K, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan).
Ohama H, et al. Among authors: toyoda h.
J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553. Online ahead of print.
J Gastroenterol Hepatol. 2024.
PMID: 38602340